Resmed Q1 2027 earnings

RMD · 2026-10-29 16:05 AMC ET · 8-K on SEC

Revenue growth slowed to 6% with a 30 bp gross margin expansion, while EPS rose 23% driven by margin improvement and share count reduction.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.415B+6.0%—Ex. 99.1, income statement
EPS (GAAP)$2.92+23.0%—Ex. 99.1, income statement
EPS (adjusted)$2.91+14.0%—Ex. 99.1, income statement
Net income$418M+20.0%—Ex. 99.1, income statement
Adj. EBITDA$506M+5.0%—Ex. 99.1, income statement
Adj. EBITDA margin35.8%-0.3 pp—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 61.5% (prior 61.2%, change +30 bps)
  • Operating expenses $417.6M (+12.0% YoY)
  • One-offs in the quarter Restructuring and business transformation expenses: $29M; Acquisition and divestment related expenses: $10M; Gain on divestment of subsidiary: $55M; Income tax effect of interest income on tax refunds: $12M
  • Effective tax rate 22.4% (prior 22.0%)
  • Non-GAAP bridge Adds back amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment related expenses, gains on divestment of subsidiaries, and associated tax effects.

KPIs

MetricActualPrior quarterPrior yearChange
Operating cash flow$422M$455M$457M-8.0%
Free cash flow$374M$404M$414M-10.0%

Guidance

MetricGuidePrior guideChange
Non-GAAP diluted earnings per share$10.80 - $11.20$10.43 - $10.43+3.4% - +7.4%

What drove it

  • Revenue story Revenue grew 6% year-over-year, with non-GAAP core constant currency revenue growth of 7%.
  • EPS story EPS increased 23% driven by higher margins and a 2.4% reduction in diluted shares outstanding.
  • One-off check Gain on divestment of subsidiary ($55M) and restructuring and business transformation expenses ($29M) are one-time items.

The good

  • Non-GAAP gross margin expanded 50 bps YoY to 62.5%
  • Non-GAAP diluted EPS grew 14% YoY to $2.91
  • Free cash flow of $374M returned more than $1 billion to shareholders

The bad

  • GAAP revenue growth slowed to 6% from 9% YoY
  • Operating cash flow declined 8% YoY to $422M
  • Free cash flow declined 10% YoY to $374M

The ugly

  • none

Open questions

  • The release does not provide specific revenue or margin guidance for the full fiscal year 2027.
  • The filing does not disclose the specific proceeds or strategic rationale for the divestiture of MatrixCare.
Full release

Earnings: RMD — filed 2026-10-29

Resmed Inc (RMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 29, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.

“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business,” said Resmed’s Chairman and CEO, Mick Farrell. “Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”

“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”

Other Business and Operational Highlights

Financial Results and Operating Metrics

(Unaudited; $ in millions, except for per share amounts)

Discussion of First Quarter Results

All comparisons are to the prior year period unless otherwise noted

Fiscal Year 2027 guidance

Dividend program

The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian

Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.

The ex-dividend date will be November 11, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from November 11, 2026, through November 12, 2026, inclusive.

Webcast details

Resmed will discuss its first quarter fiscal year 2027 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2027 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing

+1 877-660-6853 (U.S.) or

+1 201-612-7415 (outside

U.S.) and entering the passcode 13762822. The telephone replay will be available until November 12, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our

AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement

Financial statements

Income Statement

Three Months Ended — (Unaudited; $ in millions, except for per share amounts)

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025Three Months Ended – % ChangeThree Months Ended – Constant Currency (A)
Revenue1,4151,3366.0%6.0%
Gross margin (D)61.5%61.2%30 bps
Non-GAAP gross margin (B)62.5%62.0%50 bps
Research and development expenses (D)1038915.0%13
Non-GAAP research and development expenses (B)1028716.0%14
Selling, general, and administrative expenses (D)31528212.0%11
Non-GAAP selling, general, and administrative expenses(B)2762596.0%6
Income from operations4534471.0%
Operating margin32.0%33.4%(140) bps
Non-GAAP income from operations (B)5064825.0%
Non-GAAP operating margin (B)35.8%36.1%(30) bps
Net income41834920.0%
Non-GAAP net income (B)41837512.0%
Diluted earnings per share2.922.3723.0%
Non-GAAP diluted earnings per share (B)2.912.5514.0%
Operating cash flow422457-8.0%
Free cash flow (C)374414-10.0%

Income Statement

Three Months Ended — (Unaudited; $ in thousands, except for per share amounts)

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025
Net revenue1,414,8141,335,582
Cost of sales (2)544,247517,918
Gross profit (2)870,567817,664
Research and development (2)102,86089,479
Selling, general, and administrative (2)314,723281,648
Total operating expenses417,583371,127
Income from operations452,984446,537
Other income (expenses), net:
Interest (expense) income, net16,3848,793
Gain (loss) attributable to equity method investments1,8841,489
Gain (loss) on equity investments5,719-6,190
Other, net62,184-3,836
Total other income (expenses), net86,171256
Income before income taxes539,155446,793
Income taxes120,74298,257
Net income418,413348,536
Basic earnings per share2.932.38
Diluted earnings per share2.922.37
Non-GAAP diluted earnings per share (1)2.912.55
Basic shares outstanding142,989146,182
Diluted shares outstanding143,411146,899

Income Statement

Three Months Ended — measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025
GAAP total revenue growth6.0%9.0%
Impact of:
Acquisitions/divestitures (A)1
Effect of foreign currency fluctuations (A)-1
Non-GAAP core constant currency total revenue growth7.0%8.0%

Income Statement

Three Months Ended September 30, 2026 — (Unaudited; $ in millions, except for per share amounts)

Three Months Ended September 30, 2026 – Gross profitThree Months Ended September 30, 2026 – Research and development expensesThree Months Ended September 30, 2026 – Selling, general, and administrative expensesThree Months Ended September 30, 2026 – Income from operationsThree Months Ended September 30, 2026 – Total other income (loss), netThree Months Ended September 30, 2026 – Income tax expenseThree Months Ended September 30, 2026 – Net incomeThree Months Ended September 30, 2026 – Diluted earnings per share
GAAP871103315453861214182.92
Amortization of acquired intangibles5-8144100.07
Restructuring and business transformation expenses8-1-20297220.16
Acquisition and divestment related expenses-1010100.07
Gain on divestment of subsidiary-62-7-55-0.38
Income tax effect of interest income on tax refunds-12120.07
Non-GAAP (A)884102276506241134182.91

Income Statement

Three Months Ended September 30, 2025 (in thousands)

Three Months Ended September 30, 2025 – As previously reportedThree Months Ended September 30, 2025 – Restructuring and business transformation expensesThree Months Ended September 30, 2025 – Amortization of acquired intangiblesThree Months Ended September 30, 2025 – As reclassified
Cost of sales - Sleep and Breathing Health products456,1183,1561,420460,694
Cost of sales - Residential Care Software50,8236,40157,224
Cost of sales (exclusive of amortization shown separately below)506,9413,1567,821517,918
Amortization of acquired intangible assets - Sleep and Breathing Health products1,420-1,420
Amortization of acquired intangible assets - Residential Care Software6,401-6,401
Amortization of acquired intangible assets7,821-7,821$—
Total cost of sales514,7623,156517,918
Gross profit820,820-3,156817,664
Research and development87,3232,15689,479
Selling, general, and administrative259,19410,49811,956281,648
Amortization of acquired intangible assets11,956-11,956
Restructuring expenses15,810-15,810
Total operating expenses374,283-3,156371,127
Income from operations446,537446,537

Income Statement

Three Months Ended March 31, 2026 — (Unaudited; $ in thousands)

Three Months Ended March 31, 2026 – As previously reportedThree Months Ended March 31, 2026 – Amortization of acquired intangiblesThree Months Ended March 31, 2026 – As reclassified
Cost of sales - Sleep and Breathing Health products481,7221,421483,143
Cost of sales - Residential Care Software50,8556,42957,284
Cost of sales (exclusive of amortization shown separately below)532,5777,850540,427
Amortization of acquired intangible assets - Sleep and Breathing Health products1,421-1,421
Amortization of acquired intangible assets - Residential Care Software6,429-6,429
Amortization of acquired intangible assets7,850-7,850$—
Total cost of sales540,427540,427
Gross profit890,979890,979
Research and development94,26794,267
Selling, general, and administrative285,65511,247296,902
Amortization of acquired intangible assets11,247-11,247
Total operating expenses391,169391,169
Income from operations499,810499,810

Income Statement

Three Months Ended June 30, 2026 — (Unaudited; $ in thousands)

Three Months Ended June 30, 2026 – As previously reportedThree Months Ended June 30, 2026 – Amortization of acquired intangiblesThree Months Ended June 30, 2026 – As reclassified
Cost of sales - Sleep and Breathing Health products539,9752,011541,986
Cost of sales - Residential Care Software54,1556,29060,445
Cost of sales (exclusive of amortization shown separately below)594,1308,301602,431
Amortization of acquired intangible assets - Sleep and Breathing Health products2,011-2,011
Amortization of acquired intangible assets - Residential Care Software6,290-6,290
Amortization of acquired intangible assets8,301-8,301$—
Total cost of sales602,431602,431
Gross profit861,216861,216
Research and development105,726105,726
Selling, general, and administrative296,28310,499306,782
Amortization of acquired intangible assets10,499-10,499
Total operating expenses412,508412,508
Income from operations448,708448,708

Balance Sheet

(Unaudited; $ in thousands)

September 30, 2026June 30, 2026
Current assets:
Cash and cash equivalents1,010,7421,469,234
Accounts receivable, net972,4981,036,233
Inventories1,021,358945,805
Prepaid expenses and other current assets504,323416,081
Assets held for sale457,386
Total current assets3,508,9214,324,739
Non-current assets:
Property, plant, and equipment, net601,787581,829
Operating lease right-of-use assets196,688153,167
Goodwill and other intangibles, net3,350,9133,362,312
Deferred income taxes and other non-current assets553,502543,903
Total non-current assets4,702,8904,641,211
Total assets8,211,8118,965,950
Current liabilities:
Accounts payable320,677308,923
Accrued expenses480,166494,921
Operating lease liabilities, current31,52729,141
Deferred revenue171,647162,911
Income taxes payable160,22898,108
Short-term debt159,975259,950
Liabilities held for sale41,156
Total current liabilities1,324,2201,395,110
Non-current liabilities:
Deferred revenue174,209170,951
Deferred income taxes62,65164,640
Operating lease liabilities, non-current169,447137,413
Other long-term liabilities283,965213,028
Long-term debt249,629399,415
Total non-current liabilities939,901985,447
Total liabilities2,264,1212,380,557
Stockholders’ equity
Common stock764764
Additional paid-in capital2,133,4182,190,614
Retained earnings7,578,5807,255,121
Treasury stock-3,633,335-2,778,591
Accumulated other comprehensive loss-131,737-82,515
Total stockholders’ equity5,947,6906,585,393
Total liabilities and stockholders’ equity8,211,8118,965,950

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, results of operations, new product development, new product launches, new markets for its products, the integration of acquisitions and success of strategic initiatives, including divestitures, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements. – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts) – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial

Measures

(Unaudited; $ in millions, except for per share amounts)

In addition to financial information prepared in accordance with GAAP, we use certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, and non-GAAP... (truncated)the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with

GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under

GAAP.

Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.

The non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide our detailed reconciliations to the corresponding GAAP financial measures) are adjusted for the impact of acquisitions and divestitures, amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment-related expenses, gains on divestment of subsidiaries, and associated tax effects, in addition to the tax effect of interest and penalties on tax refunds.

We have not included a reconciliation of forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial

Measures

(Unaudited; $ in millions, except for per share amounts)

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions) – End – RESMED INC. AND SUBSIDIARIES

Reclassification of Prior-period Amounts

(Unaudited;

$ in thousands)

During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. In connection with this change, we renamed “restructuring expenses” as “restructuring and business transformation expenses” to reflect the broader nature of the costs included within this category. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses.

Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows. The following table reconciles previously reported amounts to the revised presentation (in thousands):

RESMED INC. AND SUBSIDIARIES

Reclassification of Prior-period Amounts

(Unaudited;

$ in thousands)

The following tables reconcile previously reported quarterly 2026 amounts to the revised presentation (in thousands):

RESMED INC. AND SUBSIDIARIES

Reclassification of Prior-period Amounts

(Unaudited;

$ in thousands)

RESMED INC. AND SUBSIDIARIES

Reclassification of Prior-period Amounts

(Unaudited;

$ in thousands)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.